Professor, Urology, Eastern Virginia Med Sch
Urology
Dr. Paul F. Schellhammer, MD
|
|
Give Review
Paul F. Schellhammer is an expert in the field of Urology. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18/49 in Research/PrimaryCare. He received awards:"Fellow (FACS)". Paul F. Schellhammer is also published. He has 48 publications published. The lastest publication: "Metastatic castrate-resistant prostate cancer.' Paul Schellhammer accepts all Medicare patients.
Publications
- Metastatic castrate-resistant Prostate cancer.
- Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study.
- Quality of Life After Sipuleucel-T Therapy: Results From a Randomized, Double-blind Study in Patients With Androgen-dependent Prostate Cancer.
- Lower baseline Prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treat...
- Intermittent versus continuous androgen deprivation in Prostate cancer.
- Treater to target: a urologist's personal experience with Prostate cancer.
- Life after failure of traditional androgen deprivation therapy.
- Treatment options for localized Prostate cancer.
- RANDOMIZED TRIAL OF AUTOLOGOUS CELLULAR IMMUNOTHERAPY WITH SIPULEUCEL-T IN ANDROGEN DEPENDENT Prostate CANCER.
- Quality of life after open or robotic Prostatectomy, cryoablation or brachytherapy for localized Prostate cancer.
- Re: Chemoprevention of Prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced Prostate cancer.
- Glycomic characterization of Prostate-specific antigen and prostatic acid phosphatase in Prostate cancer and benign disease seminal plasma fluids.
- High-grade Prostate cancer and the Prostate cancer prevention trial.
- Guideline for the management of nonmuscle invasive Bladder cancer (stages Ta, T1, and Tis): 2007 update.
- Single center experience with third-generation cryosurgery for management of organ-confined Prostate cancer: critical evaluation of short-term outcomes, complications,...
- Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical Prostatectomy.
- Re: choices. M. I. Resnick J Urol 2006; 176: 2342.
- Practical system of assessment: an updated acronym for PSA.
- Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized Prostate cancer: a ...
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory Prostate cancer.
- Timing of androgen deprivation therapy: some questions answered, others not.
- Re: Editorial comment on Laparoscopic radical Prostatectomy: is intact organ removal attainable? Study of margin status.
- Overexpression of alpha-defensin is associated with Bladder cancer invasiveness.
- A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the Bladder: a Southwest ...
- Laparoscopic radical Prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique.
- Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized Prostate cancer.
- Laparoscopic radical Prostatectomy: is intact organ removal attainable? Study of margin status.
- Protein profiling in Urine for the diagnosis of bladder cancer.
- Contemporary management of Prostate cancer with lethal potential.
- An evaluation of bicalutamide in the treatment of Prostate cancer.
- Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
- Orthotopic treatment model of Prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.
- Voiding impairment after Prostate biopsy: does tamsulosin treatment before biopsy decrease this morbidity?
- Editorial: Improving outcomes for primary and salvage therapy of localized Prostate cancer.
- Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias.
- Laparoscopic radical Prostatectomy: decreasing the learning curve using a mentor initiated approach.
- Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data.
- Application of a novel protein chip mass spectrometry technology for the identification of Bladder cancer-associated biomarkers.
- Re: Trends in Gleason score for Prostate cancer diagnosed between 1983 and 1993.
- The pursuit of Prostate cancer in patients with a rising Prostate-specific antigen and multiple negative transrectal ultrasound-guided Prostate biopsies.
- RE: A structured debate: immediate versus deferred androgen suppression in Prostate cancer--evidence for deferred treatment.
- Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates Prostate cancer from noncancer patients.
- Sural nerve graft during laparoscopic radical Prostatectomy. Initial experience.
- Normal, benign, preneoplastic, and malignant Prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spe...
- Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes Prostate cancer from benign Prostate hyperplasia and healthy men.
- Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease Specific survival with minimum 10-year followup.
Schools
Joan Sanford I Weill Medical College Of Cornell University
Case Western University
Med College Of Virginia
Memorial Sloan Kettering
Conditions Treated
- Blood in Semen (Hematospermia)
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- Elevated PSA (Prostate Specific Antigen)
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Fellow (FACS)
Education
-
Virginia Commonwealth University Health System -
Case Western Reserve University - University Hospitals -
Weill Cornell Medical College of Cornell University
Drug Facts
| NPI NUMBER | 1760460893 | |
| NPPES Provider LastName | SCHELLHAMMER | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 234621815 | |
| NPPES Provider State | VA | |
| Specialty Description | Urology | |
| Total Claim Count | 424.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1760460893 |
| Last Name Of The Provider | SCHELLHAMMER |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Gerald H. Jordan, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Donald F. Lynch Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen B. Riggs, MD |
|
|
Dr. Paul D. McAdams, MD |
|
|
Dr. Jyoti J. Upadhyay, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David A. Gallo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy Davies, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy M. Powell, MD |